Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resista...
Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements
Beckley Psytech applies for B Corporation status as part of its commitment to have a positive impact...
B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.
CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT
‘The combination of the drug and psychotherapy is critical. What will be interesting to see is how the healthcare infrastructure reacts to that. That will vary around the world because different healthcare systems are set up differently and mental ... Read More
“The logic behind setting up Beckley Psytech was that there’s this body of evidence that’s been generated in an academic setting, in early stage, proof of concept settings. Now the next step is to actually take these drugs through the drug deve... Read More
Cosmo Feilding Mellen, Chief Executive Officer, will present at the Jefferies 2021 London Healthcare Conference, taking place in-person and virtually from 16th to 19th November, 2021.
“Unlocking the therapeutic potential of psychedelic medicine is not just a business for us, it is ...
Expert interview with Cosmo Feilding-Mellen on Beckley Psytech’s longstanding involvement in the psychedelic medicine space and best-in-class drug development team.